How to Commercialize a Biotech Innovation

Getting a therapy approved is not the same as turning it into a business. Many biotech innovations clear the regulator and still fail commercially, because commercialization is a distinct discipline with its own hard problems. This essay explains what it takes to commercialize a biotech innovation, beyond simply proving it works. It is educational and is not investment advice.

Approval is a milestone, not the finish line

Founders often treat regulatory approval as the goal, but approval only grants permission to sell. Whether anyone can actually make, deliver, price, and get paid for the product is a separate set of questions. A therapy that is approved but cannot be manufactured affordably, or that payers will not reimburse, reaches few patients and sustains no business. Commercialization is the work of answering these questions, and it begins long before approval, not after it.

Manufacturing at scale is the first hurdle

A process that produces enough material for a trial often cannot produce enough for a market, and scaling it up is a major undertaking, especially for biologics where the process shapes the product. The capitalized cost of development, estimated at roughly 2.6 billion dollars per approved drug in 2013 terms, partly reflects this difficulty (DiMasi, Grabowski, and Hansen, 2016). A company that has not solved reliable, affordable manufacturing at commercial scale cannot commercialize, no matter how strong its data. This is why manufacturing is treated as a strategic asset, as argued in the analysis of the manufacturing moat.

Reimbursement decides whether the market is real

In healthcare, the patient is rarely the payer. Insurers and government programs decide whether and how much to reimburse, and that decision determines whether a therapy has a viable market. A product can be approved and clinically valuable yet commercially stranded if payers decline to cover it at a sustainable price. Securing reimbursement requires evidence that the therapy delivers value relative to its cost, which means commercial strategy must shape evidence generation well before launch. Reimbursement is, in practice, a second approval that companies often underestimate.

Pricing is a strategic decision, not a number

Pricing a biotech product balances the value it delivers, what payers will accept, the cost of making it, and the need to fund future development. Price too high and payers resist or restrict access; price too low and the business cannot sustain itself or recoup its enormous development cost. Pricing also interacts with reimbursement and with public scrutiny, making it one of the most consequential and contested decisions a company makes. It cannot be set in isolation from the evidence and market-access strategy built around it.

Market access and the commercial organization

Reaching prescribers and patients requires an organization that most research-stage biotechs do not have: medical affairs, market access teams, distribution, and often a sales force. Building or partnering for this capability is expensive and slow, which is one reason many biotechs choose to be acquired by larger companies that already have it rather than commercialize alone. The decision of whether to build a commercial organization or partner for one is a defining strategic choice, and getting it wrong is a common way that good science fails to become a successful product.

The regulatory label shapes the commercial opportunity

The approved label, the precise description of which patients a therapy is approved for and on what evidence, defines the commercial market. A narrow label limits the addressable population, while a broader one expands it, and the label is itself a product of the regulatory strategy chosen years earlier. This is one more way that regulatory and commercial strategy are linked, a connection developed in why FDA strategy determines valuation. Commercialization planning that ignores the label risks building a business larger than the approval supports.

Why great science still fails without this

The recurring lesson is that scientific success and commercial success are different achievements, and the second does not follow automatically from the first. Companies that treat manufacturing, reimbursement, pricing, and market access as late-stage details rather than as core strategy frequently watch good therapies underperform or stall. Building commercialization capability deliberately, and early, is what turns an innovation into an enduring business. The broader pattern of how this breaks down is the subject of why biotech startups fail, and the underlying science is surveyed, for general readers, in the cancer research library. For how this is navigated in practice, see the advisory practice.

Build versus partner: the central commercialization choice

The defining strategic decision in commercialization is whether to build a commercial organization or to partner with, or be acquired by, a company that already has one. Building means investing years and large sums in manufacturing, market access, and a sales force, with the reward of capturing more value if it succeeds. Partnering or selling means giving up some of that value in exchange for the reach and capability of an established player, and for the reduction in execution risk that comes with it. Neither choice is universally right. It depends on the therapy, the market, the capital available, and the team's capabilities. Many biotechs conclude that they are better at discovery and development than at commercialization and choose acquisition, which is why so many exits take that form. The mistake is not choosing one path or the other, but failing to decide deliberately and early, and then discovering at launch that the company is neither built to commercialize nor positioned to partner well. Making this choice consciously is part of the strategic discipline described in the biotech investment lifecycle.